Atom Therapeutics Advances ABP-745 into Phase 2 ASCVD Trial
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
ASCVD
Advertisement
Pulse Biosciences Secures FDA IDE Approval to Launch Clinical Trial of nsPFA Cardiac Surgery System for Atrial Fibrillation
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
Novartis to Acquire Tourmaline Bio, Expanding ASCVD Pipeline
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
Advertisement
